Testing for HER2 in breast cancer: Current pathology challenges faced in Canada

Current Oncology

Volumn 19, Issue 6, 2012, Pages 315-323

  Hanna, W ^a   Barnes, P ^b   Berendt, R ^c   Chang, M ^a,d   Magliocco, A ^e   Mulligan, A M ^a,f   Rees, H ^g   Miller, N ^a,h   Elavathil, L ⁱ   Gilks, B ^j   Pettigrew, N ^k   Pilavdzic, D ^l   Sengupta, S ^m  

^a UNIVERSITY OF TORONTO   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f TORONTO GENERAL HOSPITAL   (Canada)

^g Saskatoon City Hospital   (Canada)

^h UNIVERSITY HEALTH NETWORK   (Canada)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^k UNIVERSITY OF MANITOBA   (Canada)

^l MCGILL UNIVERSITY   (Canada)

^m QUEEN S UNIVERSITY   (Canada)

more..

Author keywords

Breast cancer; HER2 testing; Pathology

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

BONE METASTASIS; BREAST BIOPSY; BREAST CANCER; CANADA; CANCER RECURRENCE; CLINICAL PRACTICE; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; JOB EXPERIENCE; MEDICAL EXPERT; NEEDLE BIOPSY; PATHOLOGIST; PRACTICE GUIDELINE; PREDICTIVE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 84870741627     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1173     Document Type: Review

References (48)

1. Wolff AC, Hammond ME, Schwartz JN, et al American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 2007;25:118-45.
2. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine Oncologist 2009;14:320-68.
3. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review J Clin Oncol 2010;28:92-8.
4. Verma S, Lavasani S, Mackey J, et al Optimizing the management of HER2-positive early breast cancer: the clinical reality Curr Oncol 2010;17:20-33.
5. Weisgerber-Kriegl U, Cirrincione A, McNiven P Estimation of the epidemiological effect of trastuzumab over 10 years in five European countries [abstract 6589] J Clin Oncol 2008;26: [Available online at http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34554; cited September 13, 2012]
6. von Minckwitz G, du Bois A, Schmidt M, et al Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study J Clin Oncol 2009;27:1999-2006.
7. Blackwell KL, Burstein HJ, Storniolo AM, et al Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer J Clin Oncol 2010;28:1124-30.
8. Sutela A, Vanninen R, Sudah M, et al Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer Acta Oncol 2008;47:38-46.
9. Shabaik A, Lin G, Peterson M, et al Reliability of HER2/ neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma Diagn Cytopathol 2011;39:328-32.
10. Khoury T, Sait S, Hwang H, et al Delay to formalin fixation effect on breast biomarkers Mod Pathol 2009;22:1457-67.
11. Yildiz-Aktas IZ, Dabbs DJ, Bhargava R The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma Mod Pathol 2012;25:1098-105.
12. HercepTest: Interpretation Manual-Breast Glostrup, Denmark: Dako Corporation; 2010 [Available online at http://www.dako.com/us/28630_19feb10_herceptest_interpretation_manualbreast_ihc_final.pdf; cited May 25, 2012]
13. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system J Clin Oncol 1999;17:1983-7.
14. Hanley KZ, Birdsong GG, Cohen C, Siddiqui MT Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needlecore, and tissue block preparations Cancer 2009;117:279-88.
15. Williams SL, Birdsong GG, Cohen C, Siddiqui MT Immunohistochemical detection of estrogen and progesterone receptor and HER2 expression in breast carcinomas: comparison of cell block and tissue block preparations Int J Clin Exp Pathol 2009;2:476-80.
16. Sumiyoshi K, Shibayama Y, Akashi S, et al Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections? Oncol Rep 2006;15:803-8.
17. Sartelet H, Lagonotte E, Lorenzato M, et al Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and cish in breast carcinoma J Clin Pathol 2005;58:864-71.
18. Vocaturo A, Novelli F, Benevolo M, et al Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era Oncologist 2006;11:878-86.
19. Almeida MM, Correia L Determination of HER-2 gene amplification by chromogenic in-situ hybridization (CISH) on fine needle aspirates from primary and metastatic breast cancer [abstract 157] Mod Pathol 2008;21(suppl 1):.
20. Dintzis SM, Allison KH Effect of formalin fixation time on HER2 expression by immunohistochemical technique [abstract 186] Mod Pathol 2010;23(suppl 1):44A.
21. Tong LC, Nelson N, Tsourigiannis J, Mulligan AM The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study Am J Surg Pathol 2011;35:545-52.
22. Yildiz-Aktas IZ, Dabbs DJ, Cooper KL, Chivukula M, McManus K, Bhargava R The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma Am J Clin Pathol 2012;137:691-8.
23. Darvishian F, Singh B, Krauter S, Chiriboga L, Gangi MD, Melamed J Impact of decalcification on receptor status in breast cancer [abstract 182] Breast J 2011;17:689-91.
24. Zustin J, Boddin K, Tsourlakis MC, et al HER-2/neu analysis in breast cancer bone metastases J Clin Pathol 2009; 62:542-6.
25. Hanna W, O'Malley FP, Barnes P, et al Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer Curr Oncol 2007;14:149-53.
26. Arnedos M, Nerurkar A, Osin P, A'Hern R, Smith IE, Dowsett M Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PGR) and HER2 status in early breast cancer (EBC) Ann Oncol 2009;20:1948-52.
27. van de Vijver MJ Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2) Eur J Cancer 2001;37(suppl 1):S11-17.
28. Tamaki K, Sasano H, Ishida T, et al Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PGR and HER2 status of breast cancer patients Cancer Sci 2010;101:2074-9.
29. D'Alfonso T, Liu YF, Monni S, Rosen PP, Shin SJ Accurately assessing HER-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed Am J Surg Path 2010;34:575-81.
30. Apple SK, Lowe AG, Rao PN, Shintaku IP, Moatamed NA Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer Mod Pathol 2009;22:1151-9.
31. Park SY, Kim KS, Lee TG, et al The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer Am J Surg 2009;197:266-9.
32. Lebeau A, Turzynski A, Braun S, et al Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies J Clin Oncol 2010;28:3264-70.
33. Lee AH, Key HP, Bell JA, Hodi Z, Ellis IO Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast Histopathology 2012;60:880-4.
34. Tsuda H, Kurosumi M, Umemura S, Yamamoto S, Kobayashi T, Osamura RY HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens BMC Cancer 2010;10:534.
35. Murray MP, Liberman L, Nehhozina T, et al Negative estrogen receptor and HER2 assays at core biopsy of invasive cancers should be confirmed in the surgical specimens [abstract 6008] Cancer Res 2009;(suppl 3):.
36. Xiao C, Gong Y, Han EY, Gonzalez-Angulo AM, Sneige N Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment Ann Oncol 2011;22:1547-53.
37. Omeroglu G, Heinmoeller P, Rüschoff J, Hanna W Concordance of the HER-2/neu status in paired primary and metastatic breast cancers: should we retest the metastatic tumors? [abstract 208] Mod Pathol 2008;21(suppl 1):.
38. National Comprehensive Cancer Network (NCCN) Breast Cancer NCCN Clinical Practice Guidelines in Oncology. Ver 1.2012 Fort Washington, PA: NCCN; 2012.
39. Broom RJ, Tang PA, Simmons C, et al Changes in estrogen receptor, progesterone receptor and HER-2/neu status with time: discordance rates between primary and metastatic breast cancer Anticancer Res 2009;29:1557-62.
40. Arnaout K, Khaliife M, Younes M, Hanbali A HER-2 status may change in recurrent breast cancer [abstract 5109] San Antonio, TX: San Antonio Breast Cancer Symposium; 2009;: [Available online at: http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_2236; cited October 11, 2012]
41. Gong Y, Booser DJ, Sneige N Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma Cancer 2005;103:1763-9.
42. MacFarlane R, Speers C, Masoudi H, Chia S Molecular changes in the primary breast cancer versus the relapsed/ metastatic lesion from a large population-based database and tissue microarray series [abstract 1000] J Clin Oncol 2008;26: [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32647; cited September 13, 2012]
43. Liedtke C, Broglio K, Moulder S, et al Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer Ann Oncol 2009;20:1953-8.
44. Houssami N, Macaskill P, Balleine R, Bilous M, Pegram MD HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis Breast Cancer Res Treat 2011;129:659-74.
45. Nakamura R, Yamamoto N, Onai Y, Watanabe Y, Kawana H, Miyazaki M Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients Breast Cancer 2012;:[Epub ahead of print].
46. Simmons C, Miller N, Geddie W, et al Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009;20:1499-504.
47. Aoyama K, Aoyama K, Kamio T, Nishikawa T, Kameoka S A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes Jpn J Clin Oncol 2010;40:613-19.
48. Fabi A, Di Benedetto A, Metro G, et al HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care Clin Cancer Res 2011;17:2055-64.